Hydrocortisone - for COVID 19 hospitalized   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.71 [0.35, 1.43]< 159%2 studies (2/-)83.2 %some concernnot evaluable moderatecrucial-
clinical improvement 1.29 [0.82, 2.03]> 10%1 study (1/-)86.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.29 [0.82, 2.03]> 10%1 study (1/-)86.5 %some concernnot evaluable moderateimportant-
death or ventilation 0.71 [0.37, 1.35]< 10%1 study (1/-)85.3 %lownot evaluable highimportant-
ventilation 0.95 [0.44, 2.04]< 10%1 study (1/-)55.3 %lownot evaluable highimportant-

-- safety endpoints 00

serious adverse events 3.01 [0.33, 27.32]< 10%1 study (1/-)16.6 %some concernnot evaluable moderateimportant-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 95,94,90,91 91